"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead
Case report
peer-reviewed

Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors: Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy



Abstract

This manuscript reports on a patient with a metastatic gastrointestinal stromal tumor (GIST) refractory to standard first-line treatment, who underwent a gallium-68 scan based on pre-clinical data of somatostatin receptor (SSTR) expression in such tumors. The gallium-68 DOTATATE scan determined significant somatostatin receptor avidity as hypothesized, suggesting that this imaging modality may be used as an option for diagnostic and follow-up purposes in GIST patients. In addition, peptide receptor-mediated radiotherapy (177Lu-PPRT) via SSTR may provide a novel treatment strategy in carefully selected SSTR-avid GIST patients with thyrosine kinase inhibitor (TKI)-resistant tumors such as this case, and this warrants further investigation in novel clinical trial concepts.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Case report
peer-reviewed

Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors: Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy


Author Information

Arturo Loaiza-Bonilla Corresponding Author

Medicine, Hematology and Oncology, Cancer Treatment Centers of America

Paula A. Bonilla-Reyes

Facultad de Medicina, Pontificia Universidad Javeriana


Ethics Statement and Conflict of Interest Disclosures

Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.


Case report
peer-reviewed

Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors: Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy


Figures etc.

Share
Case report
peer-reviewed

Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors: Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy

Arturo Loaiza-Bonilla">Arturo Loaiza-Bonilla , Paula A. Bonilla-Reyes">Paula A. Bonilla-Reyes

  • Author Information
    Arturo Loaiza-Bonilla Corresponding Author

    Medicine, Hematology and Oncology, Cancer Treatment Centers of America

    Paula A. Bonilla-Reyes

    Facultad de Medicina, Pontificia Universidad Javeriana


    Ethics Statement and Conflict of Interest Disclosures

    Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

    Acknowledgements


    Article Information

    Published: September 24, 2017

    DOI

    10.7759/cureus.1710

    Cite this article as:

    Loaiza-bonilla A, Bonilla-reyes P A (September 24, 2017) Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors: Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy. Cureus 9(9): e1710. doi:10.7759/cureus.1710

    Publication history

    Received by Cureus: July 31, 2017
    Peer review began: September 02, 2017
    Peer review concluded: September 18, 2017
    Published: September 24, 2017

    Copyright

    © Copyright 2017
    Loaiza-Bonilla et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

    License

    This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

This manuscript reports on a patient with a metastatic gastrointestinal stromal tumor (GIST) refractory to standard first-line treatment, who underwent a gallium-68 scan based on pre-clinical data of somatostatin receptor (SSTR) expression in such tumors. The gallium-68 DOTATATE scan determined significant somatostatin receptor avidity as hypothesized, suggesting that this imaging modality may be used as an option for diagnostic and follow-up purposes in GIST patients. In addition, peptide receptor-mediated radiotherapy (177Lu-PPRT) via SSTR may provide a novel treatment strategy in carefully selected SSTR-avid GIST patients with thyrosine kinase inhibitor (TKI)-resistant tumors such as this case, and this warrants further investigation in novel clinical trial concepts.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Arturo Loaiza-Bonilla

Medicine, Hematology and Oncology, Cancer Treatment Centers of America

For correspondence:
arturo.loaiza-bonilla@ctca-hope.com

Paula A. Bonilla-Reyes

Facultad de Medicina, Pontificia Universidad Javeriana

Arturo Loaiza-Bonilla

Medicine, Hematology and Oncology, Cancer Treatment Centers of America

For correspondence:
arturo.loaiza-bonilla@ctca-hope.com

Paula A. Bonilla-Reyes

Facultad de Medicina, Pontificia Universidad Javeriana